Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2021-10-18 Regulatory Filings
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience PLC, noting an announcement from its portfolio company, LogicBio Therapeutics, regarding early clinical trial results for a genome editing therapy (LB-001) in children with methylmalonic acidemia (MMA). This type of announcement, detailing clinical progress, safety data, and trial updates, is characteristic of an Earnings Release (ER) or a general Regulatory Announcement/News Service release. Since it focuses on specific, time-sensitive operational/clinical results rather than a full quarterly financial report (10-K or IR), 'ER' (Earnings Release) is the most appropriate fit for key operational updates, even if it's not strictly quarterly earnings. However, given the context of a company disseminating an announcement via a service like EQS, and the content being a specific clinical update rather than a summary of overall financial performance, it strongly aligns with a general regulatory announcement disseminated through official channels. Since 'ER' usually implies financial results (revenue, profit), and this is purely clinical trial data dissemination, the most accurate category for a non-standard, time-sensitive regulatory update that isn't a formal financial report is the general regulatory filing category, RNS, or potentially IP if it were a presentation, but it reads like a news wire release. Given the options, and that it is a formal announcement disseminated via a regulatory mechanism ('Dissemination of a Regulatory Announcement'), RNS (Regulatory Filings) serves as the best fit for this type of material that doesn't fit the specific financial report codes.
2021-10-18 English
Business Update and Cancellation of Share Buyback
Regulatory Filings Classification · 1% confidence The document is titled "Business Update and Cancellation of Share Buyback" and details strategic actions, management additions, portfolio company milestones (like IPO filings), and the decision to cease the share buyback program. This content relates to ongoing corporate strategy, financing activities, and management updates, but it is presented as a general regulatory announcement disseminated via EQS Group, rather than a formal, comprehensive report like a 10-K or IR. The key actions involve management changes (new secondee), portfolio updates, and a capital structure decision (cancelling the buyback). Since it announces strategic business developments and a change in capital allocation policy, it fits best under Capital/Financing Update (CAP) due to the explicit cancellation of the share buyback, or potentially Management Information (MANG) due to the team expansion. However, the cancellation of a share buyback is a direct capital structure event. Given the options, 'CAP' (Capital/Financing Update) is the most precise fit for the primary financial decision announced, although 'RNS' (Regulatory Filings) is a strong fallback for general regulatory news. I will classify it as CAP because the core financial action is the cessation of a capital return program.
2021-10-18 English
Transaction in own shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states its subject matter in the title and body: "Transaction in own shares". It details the purchase of 62,000 ordinary shares as part of a buyback programme, including the date, price, and resulting total shares outstanding. Furthermore, the metadata section explicitly lists the 'Category Code' as 'POS' and the 'OAM Categories' as '2.4. Acquisition or disposal of the issuer's own shares'. This directly corresponds to the definition for Transaction in Own Shares (POS).
2021-10-15 English
Transaction in own shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states the subject is 'Transaction in own shares' and details the purchase of ordinary shares as part of a 'buyback programme'. The metadata section also includes 'Category Code: POS' and 'OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares'. This directly corresponds to the definition for Transaction in Own Shares (Code: POS).
2021-10-14 English
Transaction in own shares
Transaction in Own Shares Classification · 1% confidence The document explicitly states 'Transaction in own shares' in the title and body. It details the purchase of 61,000 ordinary shares as part of a buyback programme. Furthermore, the metadata section explicitly lists the 'Category Code: POS'. This directly corresponds to the definition for 'Transaction in Own Shares (Code: POS)'.
2021-10-13 English
TR1: Notification of Major Shareholding
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR1: Notification of Major Shareholding' and contains the standard form 'TR-1: Standard form for notification of major holdings'. This form details the acquisition or disposal of voting rights, crossing a threshold, and lists the resulting shareholding percentage (e.g., 6,160,083 shares, 4.8%). The OAM Categories section also lists '2.3. Major shareholding notifications'. This directly corresponds to the definition for Major Shareholding Notification (MRQ). The document is the notification itself, not an announcement of a forthcoming report.
2021-10-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.